Ayala Pharmaceuticals Highlights Presentation Of Preliminary Clinical Data From Ongoing Phase 2 ACCURACY Trial And Announces Pre-Clinical Proof Of Concept Data For Enhanced Activity Of AL101 In Combination Aith Approved Cancer Therapies In ACC